Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Anja Engelke"'
Autor:
Sebastian Böttcher, Barbara Eichhorst, Othman Al-Sawaf, Petra Langerbeins, Anja Engelke, Matthias Ritgen, Jasmin Bahlo, Eugen Tausch, Michael Hallek, Holger Hebart, Sandra Robrecht, Michael Kneba, Paula Cramer, Anna-Maria Fink, Stephan Stilgenbauer, Kirsten Fischer, Till Seiler, Ludwig Fischer von Weikersthal, Clemens-Martin Wendtner, Julia von Tresckow, Karl-Anton Kreuzer
Publikováno v:
The Lancet Oncology. 19:1215-1228
Summary Background Targeted agents such as the type II anti-CD20 antibody obinutuzumab and the B-cell lymphoma-2 antagonist venetoclax have shown impressive therapeutic activity in chronic lymphocytic leukaemia. The CLL2-BAG trial was initiated to in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37706b78190a6ac1d4c394ed531de164
https://doi.org/10.1016/s1470-2045(18)30414-5
https://doi.org/10.1016/s1470-2045(18)30414-5
Autor:
Sebastian Böttcher, Petra Langerbeins, Clemens-Martin Wendtner, Julia von Tresckow, Michael Hallek, Paula Cramer, Jasmin Bahlo, Stephan Stilgenbauer, Anna-Maria Fink, Kirsten Fischer, Barbara Eichhorst, Anja Engelke, Karl-Anton Kreuzer
Publikováno v:
Future Oncology. 14:499-513
Aim: Four Phase II trials (clinical trials numbers: NCT02345863, NCT02401503, NCT02445131 and NCT02689141) evaluate a different combination of targeted agents in an all-comer population of approximately 60 patients with chronic lymphocytic leukemia i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e44b301b8e75ee2b877c7fd762635d86
https://doi.org/10.2217/fon-2017-0442
https://doi.org/10.2217/fon-2017-0442
Publikováno v:
Drug Design, Development and Therapy
For decades, treatment of chronic lymphocytic leukemia (CLL) has been based on chemotherapy. This changed when the first CD20 antibody rituximab was introduced. Since 2008, the combination of chemotherapy and CD20 antibodies has become the standard o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2112bdfa319a651074817ca19571e937
https://doi.org/10.2147/dddt.s104869
https://doi.org/10.2147/dddt.s104869
Autor:
Hartmut Döhner, Eugen Tausch, Stephan Stilgenbauer, Giuliano Crispatzu, Anja Engelke, Joanna Schiller, Marion Klaumünzer, Peter Nürnberg, Michael Hallek, Carmen D. Herling, Cristiano Krings Rocha, Kirsten Fischer, Hans Christian Reinhardt, Sandra Kluth, Janine Altmüller, Karl Anton Kreuzer, Marco Herling, Holger Thiele, Jasmin Bahlo, Valentin Goede
Publikováno v:
Blood. 128:395-404
Genetic instability is a feature of chronic lymphocytic leukemia (CLL) with adverse prognosis. We hypothesized that chromosomal translocations or complex karyotypes and distinct somatic mutations may impact outcome after first-line chemoimmunotherapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::86f2acea2f1ce9ee0d62f9c9aa14fba1
https://doi.org/10.1182/blood-2016-01-691550
https://doi.org/10.1182/blood-2016-01-691550
Autor:
Othman Al-Sawaf, Michael Kneba, Till Seiler, Petra Langerbeins, A. M. Fink, Sandra Robrecht, C M Wendtner, Jasmin Bahlo, Paula Cramer, Michael Hallek, Kirsten Fischer, S. Stilgenbauer, Matthias Ritgen, L. Fischer von Weikersthal, Anja Engelke, Barbara Eichhorst, J. von Tresckow, Karl-Anton Kreuzer, Holger Hebart
Publikováno v:
Hematological Oncology. 35:25-27
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7583b8fd13183601195c90a31920d5f5
https://doi.org/10.1002/hon.2437_5
https://doi.org/10.1002/hon.2437_5
Autor:
Javier de la Serna, Stephen Opat, Elina Asikanius, Tatiana Chagorova, Thomas Illmer, Hartmut Döhner, Clemens M. Wendtner, Michael Hallek, Michael Kneba, Kirsten Fischer, Matthias Ritgen, Marie-Sarah Dilhuydy, Kathryn Humphrey, Carolyn Owen, Anja Engelke, Valentin Goede, Karl-Anton Kreuzer, Barbara Eichhorst, Stephan Stilgenbauer, Raymonde Busch, Anton W. Langerak, Michael Wenger, Olga Samoylova
Publikováno v:
New England Journal of Medicine, 370(12), 1101-1110. Massachussetts Medical Society
A B S T R AC T Background The monoclonal anti-CD20 antibody rituximab, combined with chemotherapeutic agents, has been shown to prolong overall survival in physically fit patients with previously untreated chronic lymphocytic leukemia (CLL) but not i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8b5b790169aa85d6818b5c82c608973
https://doi.org/10.1056/nejmoa1313984
https://doi.org/10.1056/nejmoa1313984
Autor:
Stéphane Leprêtre, Kathryn Humphrey, Marco Montillo, R Schlag, Valentin Goede, Christopher Fegan, Elina Asikanius, Anja Engelke, L F C Montero, Kirsten Fischer, Michael Hallek, Günter Fingerle-Rowson
Publikováno v:
Leukemia. 29:1602-1604
Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b865fe917fc84b69be20b307112690a
https://doi.org/10.1038/leu.2015.14
https://doi.org/10.1038/leu.2015.14
Autor:
Stephan Stilgenbauer, Hartmut Döhner, Paula Marlton, Marco Herling, Barbara Eichhorst, Paula Cramer, Eugen Tausch, Michael Hallek, Clemens M. Wendtner, Paolo Ghia, Karl Anton Kreuzer, Jasmin Bahlo, Christian Maurer, Julia von Tresckow, Carmen D. Herling, Sebastian Böttcher, Valentin Goede, Anja Engelke, Petra Langerbeins, Michael Kneba, Kirsten Fischer, Anna-Maria Fink, John F. Seymour, Gabor Kovacs
Despite promising results with targeted drugs, chemoimmunotherapy with fludarabine, cyclophosphamide (FC), and rituximab (R) remains the standard therapy for fit patients with untreated chronic lymphocytic leukemia (CLL). Herein, we present the long-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35ca9faa6228f111f66fd431e5112f68
http://www.bloodjournal.org/content/bloodjournal/127/2/208.full.pdf
http://www.bloodjournal.org/content/bloodjournal/127/2/208.full.pdf
Autor:
Anna-Maria Fink, Kirsten Fischer, Sandra Robrecht, Paula Cramer, Barbara Eichhorst, Petra Langerbeins, Anja Engelke, Stephan Stilgenbauer, Othman Al-Sawaf, Moritz Fürstenau, Michael Hallek, Jasmin Bahlo, Sebastian Boettcher, Von Tresckow Julia, Clemens M. Wendtner, Karl Anton Kreuzer, Matthias Ritgen
Publikováno v:
Journal of Clinical Oncology. 36:7513-7513
7513Background: The German CLL study group (GCLLSG) performed three similar phase-II-trials combining a CD20-antibody, ofatumumab (O) or obinutuzumab (G, for GA-101), with ibrutinib (I) or venetocl...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ad4ef585009113b7fc49f63673c7d5b2
https://doi.org/10.1200/jco.2018.36.15_suppl.7513
https://doi.org/10.1200/jco.2018.36.15_suppl.7513
Autor:
Anja Engelke, S. Stilgenbauer, A. M. Fink, Jasmin Bahlo, Gbor Kovacs, C M Wendtner, Michael Hallek, Petra Langerbeins, Matthias Ritgen, Barbara Eichhorst, Kirsten Fischer, Natali Pflug, Till Seiler, Lutz P. Müller, J. von Tresckow, Christian Maurer, Paula Cramer
Publikováno v:
Leukemia. 30(10)
This study aimed to assess the frequency of and the contributing factors for second primary malignancies (SPMs) and Richter's transformations (RTs) following first-line treatment of chronic lymphocytic leukemia within four phase II/III trials of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df0fabb067589f2b6962afbf1b9e15ce
https://pubmed.ncbi.nlm.nih.gov/27133817
https://pubmed.ncbi.nlm.nih.gov/27133817